Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Active immunisation against measles, mumps, and rubella.
|
|
Dosage/Direction for Use
Adult : IM/SC Primary immunisation: 1 or 2 doses of 0.5 mL given at least 28 days apart or based on national recommendation. For post-exposure prophylaxis against measles: Administer within 72 hours of contact. For outbreaks: Refer to detailed product guideline or national protocol.
|
|
Dosage Details
Parenteral
Active immunisation against measles, mumps and rubella Adult: Primary immunisation: 1 dose of 0.5 mL given via IM or deep SC inj, a 2nd dose may be given at an interval of at least 28 days or based on national recommendation. For post-exposure prophylaxis against measles: Administer within 72 hours of contact. For outbreaks: Refer to detailed product guideline or national protocols.
Child: Primary immunisation: ≥12 months 1 dose of 0.5 mL at 12-15 months; repeated at 4-6 years of age (preferably prior to elementary school entry). For outbreaks: Refer to detailed product guideline or national protocols. |
|
Reconstitution
Reconstitute with the provided diluent using aseptic technique. Gently agitate to mix thoroughly.
|
|
Incompatibility
Do not mix with other vaccines. Use separate needles and syringes for each inj.
|
|
Contraindications
Hypersensitivity. Patient with current febrile respiratory illness or infections, blood dyscrasias, leukaemia, lymphomas, history of congenital or hereditary immunodeficiency, active untreated TB. Severely immunocompromised patients. Pregnancy.
|
|
Special Precautions
Patient with history of cerebral injury or seizures, coagulation disorders (e.g. thrombocytopenia), immunosuppression. Postpone vaccination in patients with moderate or severe acute febrile illness. Not indicated for post-exposure prophylaxis against mumps or rubella. Lactation.
|
|
Adverse Reactions
Significant: Inj site reactions (e.g. pain, redness, bruising, swelling, induration); syncope, fever, headache.
Gastrointestinal disorders: Nausea, vomiting. General disorders and administration site conditions: Fatigue, irritability, malaise. Metabolism and nutrition disorders: Loss of appetite. Musculoskeletal and connective tissue disorders: Myalgia. Skin and subcutaneous tissue disorders: Rash. Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis, angioedema). |
|
Parenteral: C
|
|
MonitoringParameters
Monitor for syncope and hypersensitivity reactions 15 minutes after administration.
|
|
Drug Interactions
Decreased immune response with immune globulin and immunosuppressive therapies (e.g. high-dose corticosteroids). Reduced therapeutic effect with other live vaccines.
|
|
Lab Interference
May interfere with tuberculin test.
|
|
Action
Description: Measles, mumps, and rubella (MMR) vaccine is a live attenuated vaccine, that produces active immunity against diseases caused by measles, mumps, and rubella viruses.
|
|
Storage
Store between 2-8°C. Protect from light. Do not freeze.
|
|
MIMS Class
|
|
ATC Classification
J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.
|
|
References
Anon. Measles, Mumps, and Rubella Virus Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/07/2018. Buckingham R (ed). Measles, Mumps, and Rubella Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/07/2018. Joint Formulary Committee. Measles, Mumps and Rubella Vaccine, Live. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/07/2018. M-M-R II Injection, Powder, Lyophilized, for Suspension (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/07/2018.
|
